2nd Feb 2006 11:00
AstraZeneca PLC02 February 2006 AstraZeneca Development Pipeline2 February 2006 Line Extensions Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA CV Atacand angiotensin II antagonist diabetic retinopathy III > 2008 >2008 Crestor statin atherosclerosis III 1H 2007 1H 2007 Crestor statin outcomes CHF III >2008 >2008 Crestor statin outcomes renal III 2008 2008 Seloken/ beta-blocker HCTZ combination III Launched Filed Toprol-XL Exanta thrombin inhibitor prevention of stroke III Filed** Filed* in AF GI Nexium proton pump inhibitor NSAID GI side effects III Promotable*** Filed - symptom resolution Nexium proton pump inhibitor NSAID GI side effects III Launched Filed - ulcer healing Nexium proton pump inhibitor peptic ulcer bleeding III >2008 >2008 Nexium Sachet proton pump inhibitor GERD III Q4 2006 Filed formulation Nexium proton pump inhibitor extra-oesophageal II >2008 >2008 reflux disease Neuroscience Seroquel SR D2/5HT2 antagonist schizophrenia III 3Q 2006 3Q 2006 Seroquel D2/5HT2 antagonist bipolar maintenance III 2H 2007 1H 2007 Seroquel D2/5HT2 antagonist bipolar depression III 1H 2007 Filed Seroquel SR D2/5HT2 antagonist generalised anxiety III 2008 2H 2007 disorder Seroquel SR D2/5HT2 antagonist major depressive III 2008 2008 disorder Onc/infection Merrem carbapenem antibiotic skin and soft tissue III Launched infections Faslodex oestrogen receptor 2nd line after III 2008 2008 antagonist aromatase inhibitor failure Faslodex oestrogen receptor 1st line advanced III >2008 >2008 antagonist breast cancer Faslodex oestrogen receptor adjuvant III >2008 >2008 antagonist Iressa EGFR-TK inhibitor head & neck cancer III 2H 2007 1H 2007 Iressa EGFR-TK inhibitor breast cancer II >2008 >2008 *AstraZeneca continues discussions with the FDA but the current assessment isthat it is unlikely a way forward or Exanta registration in the US will be identified. ** Switch to EU centralised procedure *** Authorities stated these symptoms were already captured within the GERDlabel. Text stating "No clinical interaction with naproxen or rofecoxib" was approved. Compound Mechanism Area under Phase Estimated Filing investigation MAA NDA Respiratory Symbicort inhaled steroid/fast Symbicort Maintenance III Filed Turbuhaler onset, long-acting ss2 and Reliever Therapy agonist for asthma (SMART) Symbicort pMDI inhaled steroid/fast asthma III Filed* Filed onset, long-acting ss2 agonist Symbicort pMDI inhaled steroid/fast COPD III Filed* 2008 onset, long-acting ss2 agonist * To be supplemented in 2008 with data supporting two additional strengths. NCE's Phase III Compound Mechanism Area under Phase Estimated Filing investigation MAA NDACVGalida PPAR agonist diabetes /metabolic III 2H 2007* 2H2007* syndrome AGI-1067 Anti-atherogenitic atherosclerosis III 1H 2007 1H 2007(Atherogenics)AZD6140 ADP receptor antagonist arterial thrombosis III >2008 >2008NeuroscienceNXY-059 (Cerovive) free radical trapping agent stroke III 1H 2007 1H 2007 Oncology/InfZactima VEGF/EGF TKI inhibitor with NSCLC III >2008 >2008 RET kinase activity(ZD6474)AZD2171 VEGF signalling inhibitor II/III >2008 >2008 (VEGFR-TKI) NSCLC and CRC * Subject to the results of Phase III studies and regulatory discussions NCE's Phases I and II Compound Mechanism Area under Phase Estimated Filing investigation MAA NDACVAZD7009 antiarrhythmic IV atrial fibrillation - II 2008 2008 conversionAZD9684 CPU inhibitor thrombosis II >2008 >2008AZD0837 thrombin inhibitor thrombosis II >2008 >2008AZD2479 (Avanir) Reverse Cholesterol dyslipidaemia I >2008 >2008 Transport enhancerAZD6610 dyslipidaemia/ I >2008 >2008 diabetesAZD8677 dyslipidaemia/ I >2008 >2008 diabetesGIAZD9056 Ion channel blocker inflammatory bowel II >2008 >2008 diseaseAZD3355 inhibitor of transient lower GERD I >2008 >2008 oesophageal sphincter relaxations (TLESR)AZD9343 inhibitor of transient lower GERD I >2008 >2008 oesophageal sphincter relaxations (TLESR)AZD9272 GERD I >2008 >2008Neuroscience AZD3480 Neuronal nicotinic receptor cognitive disorders II >2008 >2008(TC-1734,Targacept) agonistAZD9272 neuropathic pain I >2008 >2008Onc/Infection Zactima VEGF/EGF TKI inhibitor with medullary thyroid II >2008 >2008 RET kinase activity cancer(ZD6474)CytoFab (Protherics) anti-TNF-alpha polyclonal severe sepsis II >2008 >2008 antibodyZD4054 endothelin A receptor prostate cancer II >2008 >2008 antagonistPatrin (KuDOS) AGT inhibitor solid tumours II >2008 >2008AZD0530 SRC kinase inhibitor solid tumours and I >2008 >2008 haematological malignanciesAZD6244 MEK inhibitor solid tumours I >2008 >2008(ARRY-142886)AZD1152 Aurora kinase inhibitor solid tumours and I >2008 >2008 haematological malignanciesAZD4769 solid tumours I >2008 >2008KU59436 (KuDOS) PARP inhibitor breast cancer I >2008 >2008AQ4N (KuDOS) Hypoxia activated cytotoxic solid tumours I >2008 >2008 Phases I and II (continued) Compound Mechanism Area under Phase Estimated Filing investigation MAA NDARespiratoryAZD9056 ion channel blocker rheumatoid arthritis II >2008 >2008AZD9056 ion channel blocker COPD II >2008 >2008AZD8955 collagenase inhibitor osteoarthritis II >2008 >2008AZD3778 chemokine receptor rhinitis II >2008 >2008 antagonistAZD8309 chemokine receptor rheumatoid arthritis I >2008 >2008 antagonistAZD8309 chemokine receptor COPD I >2008 >2008 antagonistAZD3342 protease inhibitor COPD I >2008 >2008AZD1981 asthma I >2008 >2008 NCE's Pre Clinical Compound Mechanism Area of investigation Phase Estimated Filing MAA NDACV AZD8450 dyslipidaemia PC >2008 >2008AZD6370 diabetes PC >2008 >2008AZD8593 haemostasis PC >2008 >2008AZD1175 diabetes/obesity PC >2008 >2008AZD2207 diabetes/obesity PC >2008 >2008AZD1305 arrhythmias PC >2008 >2008AZD1092 diabetes PC >2008 >2008AZD4121 dyslipidaemia PC >2008 >2008GI AZD8081 functional GI disease PC >2008 >2008AZD6538 GERD PC >2008 >2008Neuroscience AZD3102 Alzheimer's disease PC >2008 >2008AZD1080 Alzheimer's disease PC >2008 >2008AZD2327 anxiety PC >2008 >2008AZD5904 multiple sclerosis PC >2008 >2008AZD6538 neuropathic pain PC >2008 >2008AZD8797 multiple sclerosis PC >2008 >2008AZD3783 anxiety and depression PC >2008 >2008AZD1940 nociceptive and PC >2008 >2008 neuropathic pain.AZD9335 neuropathic pain PC >2008 >2008AZD3241 Parkinson's disease PC >2008 >2008 Pre Clinical (continued) Compound Mechanism Area of investigation Phase Estimated Filing MAA NDAOnc/Infection AZD9935 VEGF signalling inhibitor solid tumours PC >2008 >2008 (VEGFR-TKI)AZD0424 SRC kinase inhibitor solid tumours PC >2008 >2008AZD8931 solid tumours PC >2008 >2008AZD4877 solid tumours PC >2008 >2008AZD7762 solid tumours PC >2008 >2008AZD5180 (Abgenix) solid tumours PC >2008 >2008AZD1845 solid tumours PC >2008 >2008AZD8330 solid tumours PC >2008 >2008AZD3646 solid tumours and PC >2008 >2008 haematological malignanciesRespiratory AZD6067 protease inhibitor COPD PC >2008 >2008AZD6703 rheumatoid arthritis PC >2008 >2008AZD6357 Osteoarthritis PC >2008 >2008AZD7928 COPD PC >2008 >2008AZD2914 COPD PC >2008 >2008AZD2392 asthma/rhinitis PC >2008 >2008AZD1744 asthma/rhinitis PC >2008 >2008AZD5672 rheumatoid arthritis PC >2008 >2008AZD3825 asthma PC >2008 >2008AZD1236 COPD PC >2008 >2008AZD4818 COPD PC >2008 >2008AZD5069 COPD PC >2008 >2008AZD9668 COPD PC >2008 >2008AZD9215 asthma PC >2008 >2008AZD1678 asthma PC >2008 >2008AZD6605 osteoarthritis PC >2008 >2008 AstraZeneca Development PipelineDiscontinued Projects vs HY 28 July 05 CV NCE/Line Extension Compound Area under investigationNCE AZD7009 Antiarrythmic oral atrial fibrillation - maintenanceNCE AZD7806 dyslipidaemiaNCE AZD4619 dyslipidaemiaNCE AZD8294 dyslipidaemia Neuroscience NCE/Line Extension Compound Area under investigationNCE AZD7371 overactive bladderNCE AZD4282 neuropathic pain Oncology and Infection NCE/Line Extension Compound Area under investigationNCE AZD3409 solid tumoursNCE AZD5438 solid tumoursNCE ZD6126 solid tumoursNCE AZD4440 solid tumours Respiratory and Inflammation NCE/Line Extension Compound Area under investigationNCE AZD3778 Indication asthma Comments As disclosure of compound information is balanced by the business need tomaintain confidentiality, information in relation to some compounds listed here has not been disclosed atthis time. Compounds in development are displayed by phase. Abbreviations: PC - Pre-clinical: Candidate Drug accepted for development but not yet administered to man.MAA - Marketing Authorisation Application (Europe)NDA - New Drug Application (USA) This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca